Literature DB >> 19451422

Targeting renal cell carcinoma.

Robert J Motzer, Ana M Molina.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19451422     DOI： 10.1200/JCO.2009.21.8461

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  32 in total

1.  mTORC1 activation in childhood ependymoma and response to sirolimus.

Authors:  Daniel C Bowers; Blanka Kucejova; Linda Margraf; Lynn Gargan; James Brugarolas
Journal:  J Neurooncol       Date:  2010-11-13       Impact factor: 4.130

2.  Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial.

Authors:  B Walter; I Schrettenbrunner; M Vogelhuber; J Grassinger; K Bross; J Wilke; T Suedhoff; A Berand; W F Wieland; S Rogenhofer; R Andreesen; A Reichle
Journal:  Med Oncol       Date:  2011-05-24       Impact factor: 3.064

3.  Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma.

Authors:  Michael J Zelefsky; Carlo Greco; Robert Motzer; Juan Martin Magsanoc; Xin Pei; Michael Lovelock; Jim Mechalakos; Joan Zatcky; Zvi Fuks; Yoshiya Yamada
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-05-17       Impact factor: 7.038

4.  Inhibition of GSK-3 induces differentiation and impaired glucose metabolism in renal cancer.

Authors:  Krishnendu Pal; Ying Cao; Irina N Gaisina; Santanu Bhattacharya; Shamit K Dutta; Enfeng Wang; Hendra Gunosewoyo; Alan P Kozikowski; Daniel D Billadeau; Debabrata Mukhopadhyay
Journal:  Mol Cancer Ther       Date:  2013-12-10       Impact factor: 6.261

5.  Long non-coding RNA PCAT1 drives clear cell renal cell carcinoma by upregulating YAP via sponging miR-656 and miR-539.

Authors:  Rui Wang; Bin Zheng; Hongyan Liu; Xiuxian Wan
Journal:  Cell Cycle       Date:  2020-04-14       Impact factor: 4.534

6.  Upregulation of long non-coding RNA MALAT1 correlates with tumor progression and poor prognosis in clear cell renal cell carcinoma.

Authors:  Hai-min Zhang; Feng-qiang Yang; Shao-Jun Chen; Jianping Che; Jun-hua Zheng
Journal:  Tumour Biol       Date:  2014-12-06

7.  SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer.

Authors:  Guoqiang Li; Weimin Ci; Subhradip Karmakar; Ke Chen; Ruby Dhar; Zhixiang Fan; Zhongqiang Guo; Jing Zhang; Yuwen Ke; Lu Wang; Min Zhuang; Shengdi Hu; Xuesong Li; Liqun Zhou; Xianghong Li; Matthew F Calabrese; Edmond R Watson; Sandip M Prasad; Carrie Rinker-Schaeffer; Scott E Eggener; Thomas Stricker; Yong Tian; Brenda A Schulman; Jiang Liu; Kevin P White
Journal:  Cancer Cell       Date:  2014-03-20       Impact factor: 31.743

Review 8.  The VEGF pathway in cancer and disease: responses, resistance, and the path forward.

Authors:  Mark W Kieran; Raghu Kalluri; Yoon-Jae Cho
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

Review 9.  Manipulating the epigenome for the treatment of urological malignancies.

Authors:  Colm J O'Rourke; Vinicius Knabben; Eva Bolton; Diarmaid Moran; Thomas Lynch; Donal Hollywood; Antoinette S Perry
Journal:  Pharmacol Ther       Date:  2013-01-24       Impact factor: 12.310

10.  Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients.

Authors:  Ana L Teixeira; Marta Ferreira; Joana Silva; Mónica Gomes; Francisca Dias; Juliana I Santos; Joaquina Maurício; Francisco Lobo; Rui Medeiros
Journal:  Tumour Biol       Date:  2013-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.